These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8174269)

  • 21. Pathogenesis of type I hyperlipoproteinemia.
    Gnasso A; Koch H; Haberbosch W; Fellin R; Postiglione A; Augustin J
    Monogr Atheroscler; 1986; 14():135-9. PubMed ID: 3736552
    [No Abstract]   [Full Text] [Related]  

  • 22. Increased Frequency of Apo E-ND phenotype and hyperapobeta-lipoproteinemia in normolipidemic subjects with xanthelasmas of the eyelids.
    Douste-Blazy P; Marcel YL; Cohen L; Giroux JM; Davignon J
    Ann Intern Med; 1982 Feb; 96(2):164-9. PubMed ID: 7059063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine.
    Shafrir E
    Isr J Med Sci; 1996 Jun; 32(6):390-7. PubMed ID: 8682644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Apolipoprotein E and apolipoprotein E phenotype].
    Matsunaga A
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():114-6. PubMed ID: 15658277
    [No Abstract]   [Full Text] [Related]  

  • 25. [Fibrinolytic capacity after exertion in atherogenic hyperlipoproteinemias].
    Zdrenghea D; Mărcuşu C; Cucuianu M; Rentsch S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(5):435-40. PubMed ID: 44567
    [No Abstract]   [Full Text] [Related]  

  • 26. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secretion of lipoproteins, apolipoprotein A-I and apolipoprotein E by isolated and perfused liver of rat with experimental nephrotic syndrome.
    Calandra S; Gherardi E; Fainaru M; Guaitani A; Bartosek I
    Biochim Biophys Acta; 1981 Aug; 665(2):331-8. PubMed ID: 6793079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein E phenotype frequency in type II diabetic patients with different forms of hyperlipoproteinemia.
    Parhofer KG; Richter WO; Schwandt P
    Horm Metab Res; 1990 Nov; 22(11):589-94. PubMed ID: 2272605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of anorexia nervosa with severe hyperlipoproteinemia.
    Homma Y; Homma K; Iizuka S; Iigaya K
    Int J Eat Disord; 2002 Jul; 32(1):121-4. PubMed ID: 12183941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [On the clinical importance of secondary hyperlipoproteinemia in old age (author's transl)].
    Reuter W
    Z Alternsforsch; 1979; 34(5):437-44. PubMed ID: 556295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association of hyperlipoproteinemia with dysimmunoglobulinemia.
    Brinkschmidt T; Heuck CC; Schlierf G; Buchholz L; Schmidt-Gayk H
    Atherosclerosis; 1986 Mar; 59(3):323-8. PubMed ID: 3964352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Recent trend in the research of hyperlipidemia in Japan (3). Apolipoprotein E polymorphism and hyperlipoproteinemia].
    Yamamura T
    Nihon Naika Gakkai Zasshi; 1989 Oct; 78(10):1410-3. PubMed ID: 2600498
    [No Abstract]   [Full Text] [Related]  

  • 33. [Changes in serum lipoproteins in kidney diseases. Clinical and pathogenetic aspects].
    Walther A; Mordasini R; Riesen W
    Dtsch Med Wochenschr; 1983 Mar; 108(10):385-7. PubMed ID: 6825580
    [No Abstract]   [Full Text] [Related]  

  • 34. [Serum apolipoprotein abnormalities in patients with idiopathic nephrotic syndrome].
    Zhang H; Huang WC; Tang SC
    Zhonghua Yi Xue Za Zhi; 1994 Sep; 74(9):542-4, 582-3. PubMed ID: 7842352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chylomicronemia syndrome complicating type 1 hyperlipoproteinemia with concomitant insulin-dependent diabetes].
    Wojtukiewicz MZ; Lemancewicz D; Dziecioł J; Chrostek L
    Pol Merkur Lekarski; 1999 Feb; 6(32):84-6. PubMed ID: 10337179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes in serum lipoproteins in kidney diseases. Therapeutic possibilities].
    Walther A; Mordasini R; Riesen W
    Dtsch Med Wochenschr; 1983 Mar; 108(10):388. PubMed ID: 6337805
    [No Abstract]   [Full Text] [Related]  

  • 37. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy.
    Berg AL; Nilsson-Ehle P; Arnadottir M
    Kidney Int; 1999 Oct; 56(4):1534-43. PubMed ID: 10504505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hyperlipoproteinemia in the nephrotic syndrome].
    Yasugi T; Shimizu T; Iijima M; Tomita M; Harada M
    Saishin Igaku; 1972 Mar; 27(3):504-9. PubMed ID: 5021394
    [No Abstract]   [Full Text] [Related]  

  • 39. Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria.
    Joven J; Simó JM; Vilella E; Camps J; Espinel E; Villabona C
    Clin Chem; 1995 Jun; 41(6 Pt 1):908-13. PubMed ID: 7768011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Changes in serum lipoproteins in kidney diseases].
    Mordasini R; Riesen W
    Schweiz Med Wochenschr; 1982 Sep; 112(39):1335-40. PubMed ID: 6755693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.